Navigation Links
Siemens and LabCorp Enter Agreement to Co-Develop New Clinical Diagnostic Tests
Date:5/8/2008

DEERFIELD, Ill., May 8 /PRNewswire-FirstCall/ -- Siemens Healthcare and Laboratory Corporation of America(R) Holdings (LabCorp(R)) today announced that they have entered a non-exclusive agreement to discuss future possibilities to co-develop new clinical diagnostic tests in the areas of companion diagnostics, metabolic syndrome, oncology and diabetes. Under the agreement, initial discussions will focus on developing new tests that could make the biggest impact to patient care.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070904/SIEMENSLOGO )

Companion diagnostics are tests designed to identify the suitability between patients and a particular drug therapy. The tests can be used in personalized medicine to improve safety and efficacy of therapeutic drugs and in some cases, may help determine optimal dosing for individual patients. Metabolic syndrome is becoming more common and is characterized by a person having multiple risk factors that may include high blood pressure, heart disease, obesity and diabetes, among others. It's estimated that more than 50 million people are affected by this syndrome in the United States alone(1).

Diabetes is a chronic disease currently affecting more than 180 million people worldwide and is likely to more than double by 2030(2). Early detection and treatment of diabetes may enable a patient to better maintain their lifestyle. In addition, the possibility of advancing early detection of cancer is important as it may lead to higher survival rates. One in eight deaths worldwide is due to cancer, and in 2007, there were more than 12 million estimated new cancer cases worldwide(3).

Siemens is a leader in the diagnostic industry with the broadest range of products and services used for diagnosing medical conditions and monitoring patient therapy; LabCorp is a reference laboratory successfully serving more than 220,000 clients in America. Together, the companies are well positioned to co-develop and introduce new diagnostic tests that may advance patient care through early detection and proper monitoring of disease.

"This agreement establishes a framework that gives both companies the opportunity to offer new diagnostic tests to laboratories, physicians and their patients more quickly and effectively than either could do alone," said Dave Hickey, senior vice president strategic planning and business development, Siemens Healthcare Diagnostics. "Advancing health care for patients is an important commitment that we can reach through strategic relationships such as this."

"LabCorp is excited about this strategic collaboration and its impact on our companion diagnostics efforts," said Myla P. Lai-Goldman, M.D., executive vice president, chief scientific officer and medical director for LabCorp. "Alliances, such as this between developers and providers of new tests, are critical in translating emerging biomarkers from research into clinical practice."

About Siemens Healthcare

Siemens Healthcare is one of the world's largest suppliers to the healthcare industry. The company is a renowned medical solutions provider with core competence and innovative strength in diagnostic and therapeutic technologies as well as in knowledge engineering, including information technology and system integration. With its laboratory diagnostics acquisitions, Siemens Healthcare will be the first fully integrated diagnostics company, bringing together imaging and lab diagnostics, therapy, and healthcare information technology solutions, supplemented by consulting and support services. Siemens Healthcare delivers solutions across the entire continuum of care -- from prevention and early detection, to diagnosis, therapy and care. The company employs more than 49,000 people worldwide and operates in 130 countries. In the fiscal year 2007 (Sept. 30), Siemens Healthcare reported sales of euro 9.85 billion (on a pro forma basis including Dade Behring roughly euro 11 billion), orders of euro 10.27 billion, and group profit of euro 1.32 billion. Further information can be found by visiting http://www.siemens.com/healthcare.

About LabCorp(R)

Laboratory Corporation of America(R) Holdings, a S&P 500 company, is a pioneer in commercializing new diagnostic technologies and the first in its industry to embrace genomic testing. With annual revenues of $4.1 billion in 2007, over 26,000 employees nationwide, and more than 220,000 clients, LabCorp offers clinical assays ranging from routine blood analyses to HIV and genomic testing. LabCorp combines its expertise in innovative clinical testing technology with its Centers of Excellence: The Center for Molecular Biology and Pathology, National Genetics Institute, Inc., ViroMed Laboratories, Inc., The Center for Esoteric Testing, DIANON Systems, Inc., US LABS, and Esoterix and its Colorado Coagulation, Endocrine Sciences, and Cytometry Associates laboratories. LabCorp conducts clinical trial testing through its Esoterix Clinical Trials Services division. LabCorp clients include physicians, government agencies, managed care organizations, hospitals, clinical labs, and pharmaceutical companies. To learn more about our organization, visit our Web site at: http://www.labcorp.com.

(1) American Heart Association (AHA) 2008. Web site accessed Febuary 15,

2008: http://www.americanheart.org/presenter.jhtml?identifier=4756

(2) World Health Organization (WHO) 2008. Web site accessed Feburary 15,

2008: http://www.who.int/mediacentre/factsheets/fs312/en/index.html

(3) Global Cancer Facts & Figures 2007; Publication of the American Cancer Society, Atlanta, Georgia. View this document on the following link: http://www.cancer.org/docroot/STT/content/STT_1x_Global_Cancer_Facts_and_Fi gur es_2007.asp (Due to length of URL, Please copy and paste link into browser. Remove the space if one exists).


'/>"/>
SOURCE Siemens Healthcare
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Siemens Preclinical Imaging System Helps The Methodist Hospital in Houston Further Its Research Mission
2. Siemens Showcases Its Most Comprehensive and Advanced Breast Care Portfolio
3. Siemens Medical Solutions Diagnostics Inks Agreement with KreLo Medical Diagnostics to Expand Thyroid Immunoassay Menu
4. Siemens Healthcare Diagnostics Launches B12, Folate, and Ferritin Tests on Its Dimension vista Intelligent Lab System
5. Alegent Health Sees Positive Results From Recent Clinician Usability Study Collaboration With Siemens and Motion Computing
6. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
7. Kosans Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease
8. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
9. The Heart, Diabetes, And Weight Loss Centers of New York Introduce the New Science of Metabolic Diagnosis and Weight Management
10. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
11. Keeping the Data Center Clean: ATEN Launches Industry-First KVM Switches with Antimicrobial Nanocoating to Protect Products from Bacteria Surviving on Surfaces
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... The Rebound mobile app is poised to become ... tide of prescription drug addiction. The app empowers users to ... stepping down their dosage in a safe, controlled manner while ... the first 100,000 people to sign up will enjoy 3 ... ...
(Date:9/27/2017)...  Commended for their devotion to personalized service, SMP Pharmacy ... one in the South Florida Business Journal,s 50 Fastest-Growing Companies, ... list, the national specialty pharmacy has found its niche.  To ... soon be honored by SFBJ as the 2017 Power Leader ... to receive his award in October, Bardisa said of the ...
(Date:9/25/2017)... R.I. , Sept. 25, 2017  EpiVax, ... assessment, vaccine design, and immune-engineering today announced the ... on the development of personalized therapeutic cancer vaccines. ... has provided exclusive access to enabling technologies to ... Eng., MBA will lead EpiVax Oncology as Chief ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... ProVest ... the greater Dallas, Miami, and Raleigh regions, is organizing an extended charity drive ... rare and deadly chromosome abnormality. , After struggling since birth with several health ...
(Date:10/13/2017)... ... October 13, 2017 , ... The International Association of ... of excellence for the field of eating disorders, announces the opening of early ... in Orlando, Florida at the Omni Resort at ChampionsGate. , The ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Many families have ... many long-term care insurance companies have a waiver for care if the client has ... period, when the family pays for care, is often waived, so the benefits from ...
(Date:10/13/2017)... ... October 13, 2017 , ... Talented host, actor Rob Lowe, ... in a new episode of "Success Files," which is an award-winning educational program ... investigates each subject in-depth with passion and integrity. , Sciatica occurs when the ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... treating sleep apnea using cutting-edge Oventus O2Vent technology. As many as ... disorder characterized by frequent cessation in breathing. Oral appliances can offer significant relief ...
Breaking Medicine News(10 mins):